



## NEWS RELEASE

### ANTARES PHARMA TO PRESENT AT THE 26<sup>TH</sup> ANNUAL PIPER JAFFRAY HEALTHCARE CONFERENCE

**EWING, NJ, November 25, 2014** -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present at the 26<sup>th</sup> Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 12:30 p.m. Eastern Time.

A live webcast of the presentation will be available via the "Investor Information/Webcasts" page of the Antares website, [www.antarespharma.com](http://www.antarespharma.com). A replay of the webcast will also be archived on Antares' website for 90 days following the presentation.

#### About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company markets OTREXUP<sup>™</sup> (methotrexate) injection for subcutaneous use in the treatment of adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. LEO Pharma markets OTREXUP<sup>™</sup> to dermatologists for adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot<sup>®</sup> Testosterone for testosterone replacement therapy. The Company's technology platforms include VIBEX<sup>®</sup> disposable Medi-Jet, disposable multi-use pen injectors and reusable needle-free injectors marketed as Tjet<sup>®</sup> and Zomajet<sup>®</sup> by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin<sup>®</sup> [somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX<sup>®</sup> epinephrine and several other products. In the U.S. Antares has received FDA approval for Gelnique 3%<sup>™</sup> (oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin<sup>®</sup> (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda.

#### Contact:

Jack Howarth  
Vice President, Corporate Affairs  
609-359-3016  
[jhowarth@antarespharma.com](mailto:jhowarth@antarespharma.com)